Replimune Downsizes While MeiraGTx Regains Eye Therapy
Replimune cuts staff; MeiraGTx reacquires eye gene therapy https://t.co/LqGPyNzRA3 $REPL $MGTX $JNJ $BIIB $RVMD $APLS
Novo Partners OpenAI as Ideaya's Eye Data Disappoints
Novo teams with OpenAI; Ideaya gets muted response to eye drug data https://t.co/U6sDZlMxyQ $NVO $IDYA $REGN $GSK
Off‑the‑Shelf CAR‑T Shows Promise Delaying Lymphoma Relapse
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma https://t.co/UrSNYpQFqB by @gwendolynawu $ALLO + 25%
Pancreatic Cancer Drug Nearly Doubles Survival in Trial
Revolution pancreatic cancer drug nearly doubles survival in key trial https://t.co/SvJicU0LIz @ByJonGardner $RVMD + 38%
Avalyn Targets Hard-to-Treat Lung Disease, Prepares IPO
Chasing a tough-to-treat lung disease, Avalyn plans an IPO https://t.co/743svTKTS4 by @gwendolynawu #IPO $AVLN $BMY $ABBV
Eli Lilly's GLP-1 Pill Ignites Rivalry with Novo
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk https://t.co/zM6udFvuNE by Kristin Jensen $LLY $NVO #obesity
Novo Undercuts Lilly with Pricier Wegovy; Insmed Braces for Flop
Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure https://t.co/jN9GuuOf4s $NVO $LLY $INSM $VRTX $BIIB
Gilead's $3.1B Deal Expands ADC Portfolio
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis https://t.co/xEMXvDq2LL by @gwendolynawu $GILD #biotech
Study Shows Subcutaneous Tepezza Matches Infused Version
Under-the-skin Tepezza comparable to infused version in key study, Amgen says https://t.co/rOQqbRmEpL $AMGN $VRDN - 25%
Key FDA Decisions Shaping Biotech Q2 2026
New: 5 FDA decisions to watch in the second quarter of 2026 https://t.co/AVvu8i9kgh $REPL $LLY $AXSM $PFE $ARVN $IONS $ARWR #biotech
AstraZeneca's Lung Drug Scores Unexpected COPD Trial Win
AstraZeneca lung drug gets ‘surprise’ win in COPD trials https://t.co/QuRlOQtzdT @ByJonGardner $AZN $RGN $SNY $RHHBY
Novartis Acquires Excellergy to Secure Xolair Successor
Novartis targets Xolair successor in buyout of startup Excellergy https://t.co/eGYQ2AxTd5 by @gwendolynawu $NVS $RHHBY #startups #biotech
Obesity Drug News Sinks Wave, Lifts Kodiak
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends https://t.co/20H9OXVtIB $WVE - 54% $KOD + 58%
FDA Approval Propels Denali, Boosts Rare Disease Biotech
FDA clears Denali drug in ‘clear step’ for rare disease biotechs https://t.co/x9yL4nyPaj by Kristin Jensen $DNLI #biotech
Former Acorda CEO Joins Parkinson’s Cell Therapy Startup
How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup https://t.co/93JYvJGM9I by @realJacobBell #biotech #startups
